Allakos Inc. Banner Image

Allakos Inc. has reached its limit for free report views

Work for Allakos Inc.? Upgrade Your Profile and unlock all your annual reports.

Allakos Inc.

  • Ticker ALLK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Allakos Inc. Logo Image
  • 51-200 Employees
  • Based in Redwood City, California
Allakos is a clinical-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study inMore eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies, in which lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.
4.8 / 5.0 (168)

Allakos Inc. reports have an aggregate usefulness score of 4.8 based on 168 reviews.

Allakos Inc.

Most Recent Annual Report

Allakos Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Allakos Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Allakos Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!